Director’s Bold Move: Major Stock Sale at Puma Biotechnology!

Tip Ranks
2025.11.14 02:13
portai
I'm PortAI, I can summarize articles.

Director Michael Patrick Miller sold 20,000 shares of Puma Biotechnology (PBYI) for $97,200 on November 13, 2025. Puma's recent earnings report shows increased U.S. sales of NERLYNX but declining royalty revenues and new prescriptions, especially in China. Clinical trials, including ALISCA-Breast1, are progressing well. The company updated its revenue and net income estimates. Analysts have mixed views, with Spark rating PBYI as Neutral due to financial improvements and challenges in revenue consistency.

New insider activity at Puma Biotechnology ( (PBYI) ) has taken place on November 13, 2025.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Director Michael Patrick Miller recently made headlines by selling 20,000 shares of Puma Biotechnology stock, amounting to a transaction worth $97,200.

Recent Updates on PBYI stock

Puma Biotechnology’s recent earnings call and financial report reveal a mixed yet optimistic outlook. The company reported an increase in U.S. net sales of its breast cancer drug NERLYNX, contributing to a positive net income and signaling financial stability. However, challenges persist with a significant decline in royalty revenues and new prescription rates, primarily due to reduced sales in China and difficulties in patient uptake. Despite these hurdles, Puma’s clinical trials are progressing well, particularly with the ALISCA-Breast1 trial, and there is robust demand growth in the SD channel. The company remains confident in its strategic direction, updating its full-year revenue and net income estimates, and anticipates key milestones in its clinical trials over the next year. These developments have influenced analysts’ price target changes, reflecting both the positive financial trends and the challenges in international sales and new patient acquisition.

Spark’s Take on PBYI Stock

According to Spark, TipRanks’ AI Analyst, PBYI is a Neutral.

Puma Biotechnology’s overall stock score reflects its financial improvements, technical momentum, and attractive valuation. However, the company’s challenges with revenue consistency and leverage, combined with mixed earnings call insights, temper the outlook. Long-term prospects may depend on successful execution of strategic initiatives and stabilization of revenue.

To see Spark’s full report on PBYI stock, click here.

More about Puma Biotechnology

YTD Price Performance: 59.94%

Average Trading Volume: 606,043

Technical Sentiment Signal: Buy

Current Market Cap: $251.5M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer